GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2009

Clovis Oncology Raises $145M in Start-Up Financing

Clovis Oncology Raises $145M in Start-Up Financing

Clovis raises $145M in start-up funds

  • Clovis Oncology, a newly formed company focused on acquiring, developing, and commercializing anti-cancer agents, has secured $145 million in start-up financing.

    Founded by former executives of Pharmion Corporation, which was acquired by Celgene in 2008 for $2.9 billion, Clovis says it intends to acquire rights to or license innovative anti-cancer compounds in all stages of clinical development, and develop and market them in the U.S. and Europe.

    "Clovis is focused on partnering with these discovery-based companies and taking responsibility for developing and commercializing innovative products that may ultimately provide significant benefit to cancer patients," says Patrick J. Mahaffy, Clovis' president and CEO.

    Investors in Clovis include Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company's management team.ADNFCR-2184-ID-19181278-ADNFCR

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »